Figures & data
Figure 1. HbA1c values in obese hypogonadal DM2 patients before and after one year of TRT or placebo (intra- and inter-group differences and corresponding p values shown in ); HbA1c: glycated hemoglobin A1c (%), P: placebo group, T: testosterone group, time point T0: before and T1: after one year of study.
![Figure 1. HbA1c values in obese hypogonadal DM2 patients before and after one year of TRT or placebo (intra- and inter-group differences and corresponding p values shown in Table 1); HbA1c: glycated hemoglobin A1c (%), P: placebo group, T: testosterone group, time point T0: before and T1: after one year of study.](/cms/asset/10c4a359-a155-4b17-a4b4-47b2f57f0964/itam_a_1468429_f0001_b.jpg)
Table 1. Anthropometric and metabolic parameters in obese hypogonadal DM2 patients before in after one year of TRT or placebo.
Figure 2. HOMA-IR in obese hypogonadal DM2 patients before and after one year of TRT or placebo (intra- and inter-group differences and corresponding p values shown in ); HOMA-IR (homeostasis model assessment insulin resistance index), P: placebo group, T: testosterone group, time point T0: before and T1: after one year of study.
![Figure 2. HOMA-IR in obese hypogonadal DM2 patients before and after one year of TRT or placebo (intra- and inter-group differences and corresponding p values shown in Table 1); HOMA-IR (homeostasis model assessment insulin resistance index), P: placebo group, T: testosterone group, time point T0: before and T1: after one year of study.](/cms/asset/f41de8b3-08a8-423e-bded-29c09fcf03a2/itam_a_1468429_f0002_b.jpg)
Table 2. Testosterone levels in obese hypogonadal DM2 patients before and after one year of TRT or placebo.
Figure 3. FMD in obese hypogonadal DM2 patients before and after one year of TRT or placebo (intra- and inter-group differences and corresponding p values shown in ); FMD (flow mediated dilatation, %), P: placebo group, T: testosterone group, time point T0: before and T1: after one year of study.
![Figure 3. FMD in obese hypogonadal DM2 patients before and after one year of TRT or placebo (intra- and inter-group differences and corresponding p values shown in Table 3); FMD (flow mediated dilatation, %), P: placebo group, T: testosterone group, time point T0: before and T1: after one year of study.](/cms/asset/8397132b-1566-4e56-90c7-c6dc9da8c635/itam_a_1468429_f0003_b.jpg)
Table 3. FMD and IMT results in obese hypogonadal DM2 patients before and after one year of TRT or placebo.